Sridevi G

Present work is about the development of bioanalytical method of estimation for an atypical antipsychotic drug Olanzapine from endogenous matrix. Olanzapine is an atypical antipsychotic drug that chemically belongs to thieno benzodiazepine derivative. Bioanalytical estimation of antipsychotic drugs has clinical significance because of probable drug accumulation in body tissues because of long term treatment regime. Olanzapine has been recommended as the first-line drug for the treatment of schizophrenia. It is considered an atypical neuroleptic agent with fewer extrapyramidal side effects than classical neuroleptic agents. In the study initially an alternative bioanalytical estimation method, with the added advantages of decreased run time and minimization of endogenous matrix interferences was developed, which is indicated by high degree of specificity. Developed method was validated for quantization of drug Olanzapine. Developed method was finally cross validated for the estimation of Olanzapine after multiple dosing of drug in experimental animal. Result of study revealed linear detector response from 100 –500 ng/ml, with the correlation coefficient (r2 =0.989). The limit of detection and limit of quantification of the assay were 27.76 ng/ml and 79.96 and 78.55% ng/ml respectively. The recoveries of Olanzapine from plasma and brain tissue were found to be 79.96 % w/v and 78.55% w/v respectively. The applicability of the assay was confirmed for multiple dose drug determination in blood plasma and brain tissue of Olanzapine in wistar rats after i.p. administration for 10 consecutive days. This method is suitable for studying Olanzapine pharmacokinetics and toxico-kinetics in single or multiple-dose studies. Key words: Olanzapine, Bioanalytical, High Performance Liquid Chromatography.